Advanced Biomed Inc. Reports Revenue Shift to AI, Achieves Net Income of $6.7M

Advanced Biomed Inc. reported a significant shift in its business strategy and financial performance in its latest 10-K filing for the fiscal year ending June 30, 2026. The company generated approximately $127,637 in revenue, marking a transition from its previous focus on biotechnology to artificial intelligence (AI) and financial algorithmic software. This revenue was derived from agency services related to its newly acquired subsidiary, Acellent Technologies, which specializes in AI applications. In contrast, the company had no revenue from continuing operations in the prior fiscal year, reflecting its strategic pivot.

The financial results also highlighted a net income of $6,677,077 for the year, a substantial improvement from a net loss of $3,258,969 in the previous year. This increase was primarily attributed to a gain of $14,015,417 from the disposal of its former subsidiaries, Advanced Biomed HK and Advanced Biomed Taiwan. However, the company reported a loss from continuing operations of $6,261,276, which was significantly higher than the loss of $1,086,470 reported in the previous year. The increase in losses was driven by higher operating expenses, including stock-based compensation of $1,734,009 and general administrative expenses of $4,627,170, which rose by 326% compared to the prior year.

In terms of operational developments, Advanced Biomed has undergone a corporate restructuring, divesting its biomedical operations to focus entirely on AI technology. The company acquired Acellent in April 2026, integrating its FinTruth platform, which is designed for financial verification. As of June 30, 2026, the company had 12 employees, a lean structure aimed at supporting its new business model. The company plans to expand its workforce to approximately 18 employees over the next year as it seeks to enhance its product offerings and customer base.

Looking ahead, Advanced Biomed aims to generate recurring revenue through its AI technology operations, with a focus on engaging financial institutions and technology partners. The company has set ambitious goals for the next fiscal year, including deploying its FinTruth platform to 20 institutional customers and converting pilot engagements into commercial contracts. However, the company acknowledges the challenges of achieving these objectives, given its limited operating history in the AI sector and the competitive landscape it faces.

Overall, Advanced Biomed's transition to an AI-focused business model represents a significant strategic shift, with the potential for future growth contingent on successful commercialization of its technology and effective management of its operational expenses. The company is actively seeking additional financing to support its operations and plans to leverage its recent acquisitions to establish a foothold in the evolving AI market.